Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
Keyword(s):
2014 ◽
Vol 9
(2)
◽
pp. 205-213
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7525-7525
◽
Keyword(s):
2008 ◽
Vol 26
(21)
◽
pp. 3543-3551
◽
Keyword(s):
2016 ◽
Vol 96
(2)
◽
pp. E433
Keyword(s):
2009 ◽
Vol 27
(28)
◽
pp. 4787-4792
◽
Keyword(s):